NO20051423L - RNAi-prober som malsoker cancer-relaterte proteiner - Google Patents

RNAi-prober som malsoker cancer-relaterte proteiner

Info

Publication number
NO20051423L
NO20051423L NO20051423A NO20051423A NO20051423L NO 20051423 L NO20051423 L NO 20051423L NO 20051423 A NO20051423 A NO 20051423A NO 20051423 A NO20051423 A NO 20051423A NO 20051423 L NO20051423 L NO 20051423L
Authority
NO
Norway
Prior art keywords
cancer
igfbp
treatment
rnai
crush
Prior art date
Application number
NO20051423A
Other languages
English (en)
Other versions
NO334573B1 (no
Inventor
Martin Gleave
Maxim Signaevsky
Burkhard Jansen
Eliana Beraldi
Ioannis P Trougakos
Efstatjios S Gonos
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of NO20051423L publication Critical patent/NO20051423L/no
Publication of NO334573B1 publication Critical patent/NO334573B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

RNAi-sekvenser som er nyttig som terapeutika i behandlingen av cancere av ulike typer, som inkluderer prostatacancer, sarkomer slik som osteosarkom, nyrecellekarcinom, brystcancer, blærecancer, lungecancer, koloncancer, ovariccancer, anaplastisk stor cellelymfom og melanon; og Alzheimer's sykdom. Disse sekvensene målsøker klustrin, IGFBP-5, IGFBP-2, både IGFBP-2 og -5 samtidig, Mitf, og B-raf Oppfinnelsen tilveiebringer ytterligere anvendelsen av disse RNAi-sekvensene i behandlingen av cancere av ulike typer, som inkluderer prostatacancer, sarkomer slik som osteosarkom, nyrecellekarcinom, brystcancer, blærecancer, lungecancer, koloncancer, ovariecancer, anaplastisk stor cellelymfom og melanom; og Alzheimer's sykdom, og en fremgangsmåte for å behandle slike tilstander gjennom administrasjonen av RNA-molekylene med RNAi-aktivitet til et individ, som inkluderer et menneskelig individ med behov for slik behandling.
NO20051423A 2002-08-21 2005-03-17 RNA molekyler som formidler degradering eller blokkering av translasjon av mRNA som koder for klusterin, farmasøytisk sammensetning inneholdende denne samt anvendelse NO334573B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40519302P 2002-08-21 2002-08-21
US40815202P 2002-09-03 2002-09-03
US47238703P 2003-05-20 2003-05-20
PCT/CA2003/001277 WO2004018676A2 (en) 2002-08-21 2003-08-21 Rnai probes targeting cancer-related proteins

Publications (2)

Publication Number Publication Date
NO20051423L true NO20051423L (no) 2005-05-20
NO334573B1 NO334573B1 (no) 2014-04-14

Family

ID=31950539

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20051423A NO334573B1 (no) 2002-08-21 2005-03-17 RNA molekyler som formidler degradering eller blokkering av translasjon av mRNA som koder for klusterin, farmasøytisk sammensetning inneholdende denne samt anvendelse
NO20121038A NO337130B1 (no) 2002-08-21 2012-09-14 RNAi-prober som målsøker cancer-relaterte proteiner, farmasøytisk sammensetning inneholdende disse og anvendelse derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20121038A NO337130B1 (no) 2002-08-21 2012-09-14 RNAi-prober som målsøker cancer-relaterte proteiner, farmasøytisk sammensetning inneholdende disse og anvendelse derav

Country Status (10)

Country Link
US (5) US8252918B2 (no)
EP (2) EP2263679B1 (no)
JP (4) JP4717633B2 (no)
KR (3) KR101117673B1 (no)
AU (1) AU2003258426B2 (no)
CA (2) CA2494766C (no)
IL (3) IL166658A (no)
NO (2) NO334573B1 (no)
NZ (1) NZ552872A (no)
WO (1) WO2004018676A2 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE385237T1 (de) 1999-02-26 2008-02-15 Univ British Columbia Antisense-therapie für trpm-2
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP1465995B1 (en) 2002-01-17 2008-07-30 The University of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
KR101117673B1 (ko) * 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
PT1530636E (pt) 2002-08-21 2010-11-17 Univ British Columbia Tratamento do melanoma por redução dos níveis de clusterina
EP1615658A1 (en) 2003-03-25 2006-01-18 The Board Of Trustees Of The University Of Illinois Inhibition of tumor cell proliferation by foxm1b inhibitors
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US20050019918A1 (en) * 2003-06-03 2005-01-27 Hidetoshi Sumimoto Treatment of cancer by inhibiting BRAF expression
JP2005013221A (ja) * 2003-06-03 2005-01-20 Keio Gijuku Ｂｒａｆ発現抑制を利用した癌の治療
CA2560269A1 (en) * 2004-03-19 2005-09-29 The Penn State Research Foundation Combinatorial methods and compositions for treatment of melanoma
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
EP2298896A1 (en) * 2004-06-22 2011-03-23 The Board of Trustees of the University of Illinois Methods of inhibiting tumor cell proliferation with FOXM1 siRNA
CN101027412B (zh) * 2004-07-23 2017-04-26 环太平洋生物技术有限公司 用于膀胱癌检测的尿标记物
WO2006035432A2 (en) * 2004-09-27 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Gene silencing for use in dermatology
PT1814595E (pt) * 2004-11-23 2014-04-02 Univ British Columbia Tratamento de cancro com uma combinação de um agente que perturba a via de sinalização egf e um oligonucleótido que reduz os níveis de clusterina
EP1937815B1 (en) * 2005-09-13 2015-05-13 National Research Council of Canada Methods and compositions for modulating tumor cell activity
US8029980B2 (en) 2006-09-29 2011-10-04 The Board Of Trustees Of The University Of Illinois Identification and use of agents that modulate oncogenic transcription agent activity
US20090074785A1 (en) * 2007-01-16 2009-03-19 Smith Jeffrey W Compositions and methods for treatment of colorectal cancer
WO2008094516A2 (en) 2007-01-29 2008-08-07 City Of Hope Multi-targeting short interfering rnas
US20100112687A1 (en) * 2007-03-02 2010-05-06 Mdrna, Inc. Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
US8217161B2 (en) * 2008-04-22 2012-07-10 Clemson University Research Foundation Methods of inhibiting multiple cytochrome P450 genes with siRNA
WO2011063523A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
ES2763087T3 (es) * 2011-02-11 2020-05-27 Univ Rockefeller Método para la identificación de ácidos nucleicos que regulan la metastatización
WO2013123588A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
CA2844640A1 (en) 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
CN106282185B (zh) * 2016-08-18 2020-06-26 广州市锐博生物科技有限公司 一种用于抑制簇集蛋白基因表达的成套siRNA及其应用
WO2024214933A1 (ko) * 2023-04-13 2024-10-17 한양대학교 에리카산학협력단 인산화된 igfbp5의 과도한 생성을 차단하여 암을 예방 또는 치료하는 방법
KR102923964B1 (ko) * 2023-04-13 2026-02-09 한양대학교 에리카산학협력단 Igfbp5 돌연변이체 또는 이를 발현하는 벡터를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
JPWO2025041340A1 (no) * 2023-08-24 2025-02-27

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5736580A (en) * 1980-08-13 1982-02-27 Hitachi Ltd Protecting method for converter
AU663702B2 (en) * 1991-03-06 1995-10-19 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US20020086386A1 (en) * 1997-03-04 2002-07-04 Kamb Carl Alexander B-catenin assays, and compositions therefrom
US6383808B1 (en) * 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
ATE385237T1 (de) * 1999-02-26 2008-02-15 Univ British Columbia Antisense-therapie für trpm-2
WO2000069454A1 (en) * 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
IL146565A0 (en) * 1999-07-19 2002-07-25 Univ British Columbia A pharmaceutical composition containing an antisense oligonucleotide that binds to insulin-like growth factor binding protein-5
US6140126A (en) * 1999-10-26 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of Y-box binding protein 1 expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2001068836A2 (en) * 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
WO2002022642A1 (en) * 2000-09-14 2002-03-21 The University Of British Columbia Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
KR100872437B1 (ko) * 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
WO2002059300A2 (en) 2000-12-28 2002-08-01 J & J Research Pty Ltd Double-stranded rna-mediated gene suppression
EP1465995B1 (en) 2002-01-17 2008-07-30 The University of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
PT1530636E (pt) * 2002-08-21 2010-11-17 Univ British Columbia Tratamento do melanoma por redução dos níveis de clusterina
KR101117673B1 (ko) * 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ

Also Published As

Publication number Publication date
KR101212512B1 (ko) 2012-12-26
CA2882443C (en) 2016-12-13
KR20050042483A (ko) 2005-05-09
JP5662766B2 (ja) 2015-02-04
JP2013150624A (ja) 2013-08-08
NO20121038L (no) 2005-05-20
WO2004018676A3 (en) 2004-08-12
EP1532249A2 (en) 2005-05-25
EP2263679A3 (en) 2011-10-12
US20040096882A1 (en) 2004-05-20
WO2004018676A2 (en) 2004-03-04
IL166658A0 (en) 2006-01-15
AU2003258426B2 (en) 2008-04-10
KR101238701B1 (ko) 2013-03-05
KR20110122883A (ko) 2011-11-11
US9487777B2 (en) 2016-11-08
IL233352A0 (en) 2014-08-31
IL197159A0 (en) 2011-07-31
JP5171887B2 (ja) 2013-03-27
US7820635B2 (en) 2010-10-26
KR101117673B1 (ko) 2012-03-07
NO337130B1 (no) 2016-01-25
JP2010193908A (ja) 2010-09-09
AU2003258426A1 (en) 2004-03-11
US20110009472A1 (en) 2011-01-13
CA2494766A1 (en) 2004-03-04
EP2263679A2 (en) 2010-12-22
JP2006500958A (ja) 2006-01-12
NO334573B1 (no) 2014-04-14
IL197159A (en) 2016-11-30
EP2263679B1 (en) 2014-10-08
JP2011036267A (ja) 2011-02-24
IL166658A (en) 2014-11-30
KR20100135335A (ko) 2010-12-24
CA2494766C (en) 2015-05-12
US7964717B2 (en) 2011-06-21
US20060178329A1 (en) 2006-08-10
NZ552872A (en) 2007-11-30
US20080274996A1 (en) 2008-11-06
JP4717633B2 (ja) 2011-07-06
US8252918B2 (en) 2012-08-28
US20120202873A1 (en) 2012-08-09
CA2882443A1 (en) 2004-03-04
US8759308B2 (en) 2014-06-24

Similar Documents

Publication Publication Date Title
WO2004018676A3 (en) Rnai probes targeting cancer-related proteins
Jensen et al. Bcl2L13 is a ceramide synthase inhibitor in glioblastoma
Tapmeier et al. The pH low insertion peptide pHLIP Variant 3 as a novel marker of acidic malignant lesions
Metayer et al. Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence
Friedmann et al. Structure of the α-tubulin acetyltransferase, αTAT1, and implications for tubulin-specific acetylation
Herschman et al. Effect of ejaculation on serum total and free prostate-specific antigen concentrations
TNSN05300A1 (en) Treatment with anti-vegf antibodies
DK1255558T3 (da) Anti-april antistoffer og hybridomaceller
SG145559A1 (en) Genes and polypeptides relating to human colon cancers
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
Morant et al. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
Berwick et al. Sun exposure and melanoma survival: a GEM study
Tichanek et al. Survival in melanoma in the nordic countries into the era of targeted and immunological therapies
MXPA05008794A (es) Antigeno de glicoproteina sima135 expresado en celulas tumorales humanas metastasicas.
Smart et al. PK/PD mediated dose optimization of emactuzumab, a CSF1R inhibitor, in patients with advanced solid tumors and diffuse‐type tenosynovial giant cell tumor
Presant et al. Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose Methotrexate: An in vivo human study using noninvasive 19f-magnetic resonance spectroscopy
Chen et al. Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression
Blumenberg Human Skin Cancers: Pathways, Mechanisms, Targets and Treatments
Voskarides The double face of cold in cancer
Saltz Can we afford that CAR? Confronting the effect of novel immunotherapies on future health care costs
Kim et al. Frequency of genetic homologous recombination (HR) alterations in metastatic cutaneous melanoma.
Quant et al. Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM).
TW200502247A (en) Genes and polypeptides relating to human colon cancers

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees